[{"data":1,"prerenderedAt":311},["ShallowReactive",2],{"drug-risperidone":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":74,"contraindications":201,"warnings":211,"renal":263,"monitoring":273,"interactions":280,"review":281,"examples":283},"risperidone",1,{"fa":7,"en":8},"ریسپریدون","Risperidone","psychiatry",{"fa":11,"en":12},"آنتی‌سایکوتیک آتیپیک","Atypical antipsychotic",[14],{"name":15,"market":16},"Risperdal","US",[18,7,19],"risperidon","risperdal",[21,33,43,50,58,66],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":28,"refs":29},"sol-1-1","solution","oral","1 mg \u002F mL oral solution",{"amount":5,"unit":27,"perVolumeMl":5},"mg",[16],[30],{"source":31,"section":32},"fda-risperdal","3",{"id":34,"form":35,"route":24,"label":36,"concentration":37,"markets":40,"refs":41},"tab-0-5","tablet","0.5 mg tablet",{"amount":38,"unit":27,"perUnit":35,"scored":39},0.5,false,[16],[42],{"source":31,"section":32},{"id":44,"form":35,"route":24,"label":45,"concentration":46,"markets":47,"refs":48},"tab-1","1 mg tablet",{"amount":5,"unit":27,"perUnit":35,"scored":39},[16],[49],{"source":31,"section":32},{"id":51,"form":35,"route":24,"label":52,"concentration":53,"markets":55,"refs":56},"tab-2","2 mg tablet",{"amount":54,"unit":27,"perUnit":35,"scored":39},2,[16],[57],{"source":31,"section":32},{"id":59,"form":35,"route":24,"label":60,"concentration":61,"markets":63,"refs":64},"tab-3","3 mg tablet",{"amount":62,"unit":27,"perUnit":35,"scored":39},3,[16],[65],{"source":31,"section":32},{"id":67,"form":35,"route":24,"label":68,"concentration":69,"markets":71,"refs":72},"tab-4","4 mg tablet",{"amount":70,"unit":27,"perUnit":35,"scored":39},4,[16],[73],{"source":31,"section":32},[75,114,139,159,183],{"id":76,"disease":76,"label":77,"population":80,"type":87,"unit":27,"dose":88,"refs":96,"notes":101},"autism-irritability",{"fa":78,"en":79},"تحریک‌پذیری در اوتیسم — ۵ تا ۱۷ سال","Irritability with autistic disorder — 5 to 17 years",{"minAge":81,"maxAge":84,"minWeightKg":86},{"value":82,"unit":83},5,"year",{"value":85,"unit":83},18,15,"titration",{"dividedDoses":5,"weightBands":89},[90,94],{"start":91,"increment":91,"incrementEveryDays":92,"targetMin":38,"targetMax":38,"max":62,"minWeightKg":86,"maxWeightKg":93},0.25,14,20,{"start":38,"increment":38,"incrementEveryDays":92,"targetMin":5,"targetMax":5,"max":62,"minWeightKg":93,"maxWeightKg":95},null,[97,99],{"source":31,"section":98},"2.3",{"source":31,"section":100},"1.3",[102,108],{"text":103,"refs":106},{"fa":104,"en":105},"پس از حداقل ۴ روز به دوز توصیه‌شده (زیر ۲۰ کیلوگرم: ۰٫۵ mg\u002Fday؛ ۲۰ کیلوگرم به بالا: ۱ mg\u002Fday) برسانید و حداقل ۱۴ روز ادامه دهید؛ سپس افزایش با فاصله ۲ هفته یا بیشتر.","After a minimum of 4 days increase to the recommended dose (\u003C20 kg: 0.5 mg\u002Fday; ≥20 kg: 1 mg\u002Fday) and maintain for at least 14 days; further increases at intervals of ≥2 weeks.",[107],{"source":31,"section":98},{"text":109,"refs":112},{"fa":110,"en":111},"محدوده مؤثر ۰٫۵ تا ۳ mg\u002Fday. برای وزن زیر ۱۵ کیلوگرم داده‌ای وجود ندارد. کل دوز یک‌بار یا نصف آن دو بار در روز.","Effective range 0.5–3 mg\u002Fday. No dosing data below 15 kg. Total daily dose once daily, or half twice daily.",[113],{"source":31,"section":98},{"id":115,"disease":116,"label":117,"population":120,"type":87,"unit":27,"dose":124,"refs":127,"notes":132},"schizophrenia-adolescent","schizophrenia",{"fa":118,"en":119},"اسکیزوفرنی — نوجوانان ۱۳ تا ۱۷ سال","Schizophrenia — adolescents 13 to 17 years",{"minAge":121,"maxAge":123},{"value":122,"unit":83},13,{"value":85,"unit":83},{"dividedDoses":5,"titration":125},{"start":38,"increment":38,"incrementEveryDays":5,"targetMin":62,"targetMax":62,"max":126},6,[128,130],{"source":31,"section":129},"2.1",{"source":31,"section":131},"8.4",[133],{"text":134,"refs":137},{"fa":135,"en":136},"افزایش ۰٫۵ یا ۱ mg\u002Fday با فاصله ۲۴ ساعت یا بیشتر تا ۳ mg\u002Fday. بالاتر از ۳ mg\u002Fday سود اضافه دیده نشد؛ بالاتر از ۶ mg\u002Fday مطالعه نشده است.","Increase by 0.5 or 1 mg\u002Fday at intervals of ≥24 h to 3 mg\u002Fday. No added benefit above 3 mg\u002Fday; doses above 6 mg\u002Fday not studied.",[138],{"source":31,"section":129},{"id":140,"disease":116,"label":141,"population":144,"type":87,"unit":27,"dose":146,"refs":150,"notes":152},"schizophrenia-adult",{"fa":142,"en":143},"اسکیزوفرنی — بزرگسالان","Schizophrenia — adults",{"minAge":145},{"value":85,"unit":83},{"dividedDoses":5,"titration":147},{"start":54,"increment":5,"incrementEveryDays":5,"targetMin":70,"targetMax":148,"max":149},8,16,[151],{"source":31,"section":129},[153],{"text":154,"refs":157},{"fa":155,"en":156},"افزایش ۱ تا ۲ mg\u002Fday با فاصله ۲۴ ساعت یا بیشتر تا ۴ تا ۸ mg\u002Fday. بالاتر از ۶ mg\u002Fday در دو نوبت مؤثرتر نبود؛ بی‌خطری بالاتر از ۱۶ mg\u002Fday ارزیابی نشده است.","Increase by 1–2 mg\u002Fday at intervals of ≥24 h to 4–8 mg\u002Fday. Above 6 mg\u002Fday twice daily not more efficacious; safety above 16 mg\u002Fday not evaluated.",[158],{"source":31,"section":129},{"id":160,"disease":161,"label":162,"population":165,"type":87,"unit":27,"dose":169,"refs":172,"notes":176},"bipolar-pediatric","bipolar-mania",{"fa":163,"en":164},"مانیای دوقطبی — ۱۰ تا ۱۷ سال","Bipolar mania — 10 to 17 years",{"minAge":166,"maxAge":168},{"value":167,"unit":83},10,{"value":85,"unit":83},{"dividedDoses":5,"titration":170},{"start":38,"increment":38,"incrementEveryDays":5,"targetMin":5,"targetMax":171,"max":126},2.5,[173,175],{"source":31,"section":174},"2.2",{"source":31,"section":131},[177],{"text":178,"refs":181},{"fa":179,"en":180},"افزایش ۰٫۵ یا ۱ mg\u002Fday با فاصله ۲۴ ساعت یا بیشتر تا هدف ۱ تا ۲٫۵ mg\u002Fday. بالاتر از ۲٫۵ سود اضافه نداشت؛ بالاتر از ۶ mg\u002Fday مطالعه نشده است.","Increase by 0.5 or 1 mg\u002Fday at intervals of ≥24 h to target 1–2.5 mg\u002Fday. No added benefit above 2.5 mg\u002Fday; above 6 mg\u002Fday not studied.",[182],{"source":31,"section":174},{"id":184,"disease":161,"label":185,"population":188,"type":87,"unit":27,"dose":190,"refs":192,"notes":194},"bipolar-adult",{"fa":186,"en":187},"مانیای دوقطبی — بزرگسالان","Bipolar mania — adults",{"minAge":189},{"value":85,"unit":83},{"dividedDoses":5,"titration":191},{"start":54,"increment":5,"incrementEveryDays":5,"targetMin":5,"targetMax":126,"max":126},[193],{"source":31,"section":174},[195],{"text":196,"refs":199},{"fa":197,"en":198},"دوز اولیه ۲ تا ۳ mg\u002Fday؛ افزایش ۱ mg\u002Fday با فاصله ۲۴ ساعت یا بیشتر. محدوده مؤثر ۱ تا ۶ mg\u002Fday.","Initial 2–3 mg\u002Fday; adjust by 1 mg\u002Fday at intervals of ≥24 h. Effective range 1–6 mg\u002Fday.",[200],{"source":31,"section":174},[202],{"id":203,"severity":204,"text":205,"refs":208},"hypersensitivity","block",{"fa":206,"en":207},"حساسیت شناخته‌شده به ریسپریدون، پالیپریدون یا اجزای فرآورده.","Known hypersensitivity to risperidone, paliperidone or any excipient.",[209],{"source":31,"section":210},"4",[212,221,228,235,242,249,256],{"text":213,"refs":216},{"fa":214,"en":215},"هشدار جعبه‌ای: افزایش مرگ‌ومیر در سالمندان مبتلا به سایکوز ناشی از دمانس؛ برای این کاربرد تأیید نشده است.","Boxed warning: increased mortality in elderly patients with dementia-related psychosis; not approved for this use.",[217,219],{"source":31,"section":218},"Boxed Warning",{"source":31,"section":220},"5.1",{"text":222,"refs":225},{"fa":223,"en":224},"سندرم نورولپتیک بدخیم","Neuroleptic malignant syndrome",[226],{"source":31,"section":227},"5.3",{"text":229,"refs":232},{"fa":230,"en":231},"دیسکینزی دیررس","Tardive dyskinesia",[233],{"source":31,"section":234},"5.4",{"text":236,"refs":239},{"fa":237,"en":238},"تغییرات متابولیک","Metabolic changes",[240],{"source":31,"section":241},"5.5",{"text":243,"refs":246},{"fa":244,"en":245},"هایپرپرولاکتینمی","Hyperprolactinemia",[247],{"source":31,"section":248},"5.6",{"text":250,"refs":253},{"fa":251,"en":252},"افت فشار ارتوستاتیک","Orthostatic hypotension",[254],{"source":31,"section":255},"5.7",{"text":257,"refs":260},{"fa":258,"en":259},"سقوط","Falls",[261],{"source":31,"section":262},"5.8",[264],{"egfrBelow":265,"severity":266,"text":267,"refs":270},30,"warn",{"fa":268,"en":269},"نارسایی شدید کلیه (Clcr \u003C ۳۰): شروع ۰٫۵ mg دو بار در روز؛ افزایش ۰٫۵ mg یا کمتر؛ بالاتر از ۱٫۵ mg دو بار در روز با فاصله یک هفته یا بیشتر.","Severe renal impairment (Clcr \u003C30): start 0.5 mg twice daily; increase by ≤0.5 mg twice daily; above 1.5 mg twice daily at intervals of ≥1 week.",[271],{"source":31,"section":272},"2.4",[274],{"text":275,"refs":278},{"fa":276,"en":277},"پایش متابولیک (قند، چربی، وزن)","Metabolic monitoring (glucose, lipids, weight)",[279],{"source":31,"section":241},[],{"status":282,"reviewer":95,"date":95},"unverified",[284,287,291,295,299,303,308],{"regimen":76,"formulation":22,"input":285,"expect":286},{"ageYears":126,"weightKg":85},{"perDose":91,"mlPerDose":91},{"regimen":76,"formulation":22,"input":288,"expect":290},{"ageYears":289,"weightKg":265},9,{"perDose":38,"mlPerDose":38},{"regimen":76,"formulation":22,"input":292,"expect":293},{"ageYears":82,"weightKg":92},{"status":294},"blocked",{"regimen":115,"formulation":22,"input":296,"expect":298},{"ageYears":86,"weightKg":297},55,{"perDose":38},{"regimen":140,"formulation":51,"input":300,"expect":302},{"ageYears":265,"weightKg":301},70,{"perDose":54,"tabletsPerDoseRounded":5},{"regimen":160,"formulation":22,"input":304,"expect":307},{"ageYears":305,"weightKg":306},12,40,{"perDose":38},{"regimen":184,"formulation":51,"input":309,"expect":310},{"ageYears":265,"weightKg":301},{"tabletsPerDoseRounded":5},1792078540171]